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Objective To determine the incidence of candidemia in French hospitals.
Materials and methods A representative sample of 25 French hospitals [nine teaching
hospitals (TH), ten general hospitals (GH) and six cancer referral centers (CRC)] was
randomly selected. The incidence rates of candidemia per number of admissions and per
patient-days of hospitalization were determined and extrapolated to the national level.
Results From January 1, 1995 to December 31, 1995, the overall incidence rate per 1000
admissions was 0.29, ranging from 0.71/1000 in CRC, to 0.17/1000 in GH. The overall
incidence for 1000 patient-days was 0.035 and the highest incidence was also observed in
CRC (0.116/1000), followed by TH (0.052/1000). Candida albicans (53%) was the most
common species isolated, a central venous catheter (26%) was the most common portal of
entry and 50% of the candidaemic patients had a neoplasm.
Conclusion This study should enable us to optimize surveillance, prevention and
treatment of these potentially life-threatening infections.
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I N T R O D U C T I O N
According to the data published in the literature,
the incidence of nosocomial fungal infection has
increased in recent years and Candida spp. have
emerged as the fourth most common cause of noso-
comial bloodstream infections in North America
[1,2]. Although Candida albicans is the leading
cause of candidemia, the epidemiology of yeast
infections is evolving due to the emergence of
other Candida species as important pathogens.
Various risk factors for the development of
candidemia have been reported, including the
use of invasive procedures or devices, such as
intravascular catheters, and candidemia occurs
most frequently in immunocompromised patients
with underlying malignancy as well as in surgical
and intensive-care patients.
Although, candidemia represents a signifi-
cant cause of morbidity and mortality, its inci-
dence among hospitalized patients is not well
known. Most published data are fragmentary,
coming from a relatively small number of teach-
ing hospitals or cancer centers, which are not
representative of health-care facilities as a whole.
Consequently, very little is known about the fre-
quency of these infections in the general popula-
tion of hospitalized patients and no national
data are available. In order to obtain such data,
we conducted this prospective study, the main
objective of which was to determine the incidence
of candidemia in French public health-care
facilities by using a random sample of hospitals
representative of the public health-care delivery
system.
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M E T H O D S
This epidemiological study was performed in a
representative sample of French hospitals. To take
into account the specificity of the French public
health-care system, which is divided into different
categories of hospitals, the representative sample
was obtained using the following categories:
teaching hospitals (TH), general hospitals (GH),
and cancer referral centers (CRC). In each of these
categories, the number of hospitals to include was
calculated according to the importance of the cate-
gory in terms of total days of hospitalization at the
national level, and the dispersion of the activity of
each hospital in the category around the mean
activity for the category (in terms of number of
hospital-days). All the data needed for sample size
calculations were obtained from the national sta-
tistics from the Ministry of Health (Service d’Etude
Statistique et Informatique).
The country was divided into six geographic
areas of roughly equivalent importance in terms
of population: the Paris area, the North/North-
East, West, Central–Central-East, South-West, and
South-East areas. Hierarchic lists of the hospitals
from each category in each area were generated at
random. The number of hospitals from each cate-
gory to include in each sample was determined
according to the distribution of each category of
hospitals at the national level and to the number of
hospitals of each category present in each geo-
graphic area.
The head of the microbiology laboratory of the
first hospital in each list was contacted by tele-
phone by one of the investigators. If he/she was
not willing to participate, the microbiologist of the
next hospital in the same list was contacted. Before
inclusion, all participating centers were audited to
assess their capacity to detect candidemia and
identify Candida spp. by reviewing their laboratory
methods, verifying what type of blood culture
bottles, culture media and reagents were used
and determining whether clinical and administra-
tive data were available upon request. If the
laboratory did not meet the established criteria
the next hospital in the list was contacted.
In each participating centre, the following data
were prospectively collected: type of hospital (TH,
GH, CRC), number of admissions for hospitaliza-
tions lasting longer than 24 h and the correspond-
ing days of hospitalization (patient-days), total
number of blood cultures performed, number of
blood cultures positive for yeast, and results of
yeast identification.
The following data were abstracted from the
medical records of patients with candidemia:
age, sex, hospital, ward, number of specimens
collected, candidemia portal of entry, fever, under-
lying disease, neutropenia, presence of intrave-
nous and/or indwelling urinary catheters, and
antimicrobial therapy before and after the diag-
nosis of the fungal infection.
Observed data were subsequently extrapolated
to obtain national data by using a coefficient of
multiplication calculated for each hospital cate-
gory as the ratio between the number of admis-
sions and hospital-days in the sample in that
category and that of the number of admission
and hospital-days recorded at the national level
in that category during the study period.
Discrete variables were expressed as absolute
number and percentages. Quantitative variables
were expressed as the mean and standard devia-
tion (SD).
R E S U L T S
The representative sample of French hospitals
included 25 randomly selected hospitals: nine
TH, ten GH and six CRC in the six administrative
regions previously described.
Administrative data
A total of 476 718 admissions were reported by the
participating hospitals, with a total of 3 825 550
days of hospitalization (Table 1). The extrapolation
of these data to all French hospitals resulted in
Table 1 Number of admissions and days of hospitaliza-
tion in French public hospitals in 1995
Type of
hospital
Type of
data
Number
Observeda Extrapolatedb
Teaching admissions 283 656 2 765 646
days 2064 764 24 880 406
General admissions 162 107 2 635 860
days 1570 533 28 960 629
Cancer admissions 30 955 138 678
days 190 253 1 246 157
Total admissions 476 718 5 540 184
days 3825 550 55 087 192
ain a representative sample of 25 hospitals.
bat the national level.
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5 540 184 admissions and 55 087 192 days of hospi-
talization. The numbers obtained by extrapolation
were similar to the official data published by the
French Ministry of Health (Service d’Etude Statis-
tique et Informatique), showing 5 541 193 admis-
sions and 54 175 419 days of hospitalization in all
French hospitals in 1995, validating our hospital
sample as representative.
The TH accounted for 59.5% of the observed
admissions and for 54% of the days of hospitaliza-
tion, the GH accounted for 34% of the admissions
and for 41% of the days of hospitalization, while
the CRC were responsible for 6.5% of the admis-
sions and 5% of the days of hospitalization.
Blood cultures performed
The total number of blood cultures performed in
each category of hospital during the survey are
presented in Table 2. The extrapolated data show
that 1 895 710 blood cultures were performed.
Fifty-nine per cent of the blood cultures were per-
formed in TH, 39% in GH and 2% in CRC.
Table 3 shows the incidence rates of blood cul-
tures performed per admissions and per days of
hospitalization for each category of hospitals.
Blood cultures were obtained from 34.2% of inpa-
tients, with the highest rates observed in TH fol-
lowed by CRC and GH. The overall incidence rates
per days of hospitalization of blood cultures per-
formed was 4.1%, ranging from 5.5% in CRC and
in TH to 2.9% in GH.
Candidemia
As shown in Table 4, when the denominator was
the number of blood cultures performed, the
observed incidence of yeast-positive blood cul-
tures was 0.22%. The highest incidence, 0.52%,
was found in CRC while the incidence rate was
only 0.24% in TH and 0.10% in GH.
From the observed data showing that 156
patients had at least one blood culture positive
for yeasts in 1995, it was estimated that 1581
patients had developed candidemia in French
hospitals during the same period (Table 5). The
overall incidence rate per 1000 admissions was
0.285 and the overall incidence rate per 1000
patient-days was 0.035. The highest incidence of
candidemia was observed in CRC, with an inci-
dence rate per 1000 admissions of 0.711 and an
incidence rate per patient-days of 0.116, followed
by TH with an incidence rate per 1000 admissions
of 0.377 and an incidence rate per 1000 patient-
days of 0.052, and GH with an incidence rate per
1000 admissions of 0.167 and an incidence rate per
patients days of 0.017 (Table 5).
The extrapolation of the observed data indicates
that 66% of patients with candidemia were
hospitalized in TH, 28% in GH, and 6% in CRC.
The mean number of positive blood cultures
per patient was 2.6 in TH, 2.5 in CRC, and 1.6 in
GH.
Table 2 Total number of blood cultures performed in
French hospitals in 1995
Number of blood cultures
Type of hospital Observeda Extrapolatedb
Teaching 113 861 1 110 145
General 45 425 738 611
Cancer 10 481 46 955
Total 169 767 1 895 710
ain a representative sample of 25 hospitals.
bat the national level.
Table 3 Incidence rates of blood cultures performed in
French hospitals in 1995
Type of
hospital
Type of
denominator Incidence
Teaching /admissions 40.1%
/hospital days 5.51%
General /admissions 28.0%
/hospital days 2.89%
Cancer /admissions 33.9%
/hospital days 5.51%
Overall /admissions 34.2%
/hospital days 4.14%
Table 4 Number and incidence of yeast-positive blood
cultures in French hospitals in 1995
Type of
hospital
Number
Observeda Extrapolatedb
Incidence/100
blood cultures
performed
Teaching 278 711 0.24
General 44 715 0.10
Cancer 55 246 0.52
Total 377 3672 0.22
ain a representative sample of 25 hospitals.
bat the national level.
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Candida species
Whatever the type of hospital, C. albicans was the
most frequent species isolated, representing at
least 50% of the isolates, followed by C. parapsilosis,
C. glabrata, and C. tropicalis in various orders
depending on the hospital type (Table 6).
Characteristics of patients with candidemia and
portal of entry
Overall, 68% of the patients with candidemia were
male and 32% were female. Positive blood cultures
were predominantly obtained from patients hos-
pitalized in intensive-care units (ICU; 27%), fol-
lowed by surgical units (20%) and internal
medicine units (15%). Patients hospitalized in
hematology and oncology units accounted for only
10% of the patients with candidemia.
About 70% of the candidemias were hospital-
acquired infections and for 15% of them, the onset
of infection preceded the admission. The type of
acquisition (hospital- or community-acquired)
could not be determined for 15% of the patients
with candidemia. Fever (> 38 8C) was present in
84% of patients with candidemia and the following
underlying diseases were present: cancer (50%),
diabetes (5%), and trauma (4%). In addition, 23%
of the patients were neutropenic at the time of
onset of the infection.
The portal of entry for the candidemia could not
be determined for 43.1% of the patients with posi-
tive blood cultures (Table 7). A central venous
catheter, which was present in 60% of the patients
with candidemia, was considered to be the portal
of entry for 26% of them and 70% of the patients
Table 6 Yeast species most frequently isolated in blood cultures from patients hospitalized in French public hospitals in
1995
Teaching Hospitals
(na¼ 107)
%b
General Hospitals
(na¼ 27)
%b
Cancer referral centres
(na¼ 22)
%b
Total
(na¼ 156)
%b
C. albicans 51.4 59.3 50.0 52.5
C. parapsilosis 16.5 14.8 13.6 15.8
C. glabrata 9.2 18.5 13.6 11.4
C. krusei 4.6 3.7 4.6 4.4
C. tropicalis 11.9 0 9.1 9.5
C. pseudotropicalis 1.8 0 1.3 1.3
Other yeastsc 4.6 3.7 9.1 5.0
aNumber of different strains detected in patients with candidemia.
bMore than one species in some patients.
cNon-identified yeasts (mostly) or other yeasts identified.
Table 7 Portal of entry of candidemia in patients
hospitalized in French hospitals in 1995
Portal of entry %
Venous catheter 25.8
Digestive tract 11.4
Respiratory tract 7.9
Urinary tract 6.0
Operation site 0.9
Other 5.0
Undetermined 43.1
No of patients Incidence
Type of
hospital Observeda Extrapolatedb admission
/1000/1000
hospital-days
Teaching 107 1043 0.377 0.052
General 27 439 0.167 0.017
Cancer 22 99 0.711 0.116
Overall 156 1581 0.285 0.035
ain a representative sample of 25 hospitals.
bat the national level.
Table 5 Number and incidence of
patients with at least one yeast-
positive blood culture in French
hospitals in 1995
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had received broad-spectrum antimicrobial ther-
apy before the onset of the candidemia.
D I S C U S S I O N
Few surveys assessing the prevalence of candide-
mia at a national level have been reported in the
literature, and this survey is the first ever carried
out in France. In this study, three different cate-
gories of hospitals representative of the French
public and non-profit, health-care delivery system
were included and a stratified analysis was per-
formed according to the type of hospital. Although
CRC treat only patients with malignant disease,
TH and GH treat all kinds of patients, including
cancer patients. Overall, TH account for the admis-
sion of the majority of severely ill patients requir-
ing invasive procedures.
The large size of the sample, representing about
475 000 admissions and 3.8 million days of hospi-
talization per year, makes these data particularly
valuable. For extrapolation, the raw data were
weighted according to the relative importance of
each category of hospital according to the official
national data from the French Ministry of Health.
According to the extrapolated data, about 1.9
million blood cultures were performed in 1995 in
French hospitals, with 0.2% of them being positive
for Candida spp. There was a striking difference in
the incidence of blood cultures positive for yeasts
according to the category of hospital, the incidence
reaching 0.52% in CRC, twice as high as in TH
(0.24%) and five times higher than in GH (0.10%).
Unfortunately, the overall number of positive
blood cultures, irrespective of micro-organism,
was not determined in this survey, and it was
impossible to compare the proportion of blood
cultures positive for yeast to the proportion of
blood cultures positive for other micro-organisms
also responsible for bloodstream infections.
Extrapolation from our observed data showed
that about 1600 patients experienced candidemia
in 1995 in the public French hospitals. While most
of the patients with candidemia were hospitalized
in TH (66%) or in GH (28%), CRC with only 2% of
admissions and patient-days of hospitalization
accounted for 6% of all candidemia.
The differences observed between the different
categories of hospitals probably reflect the immu-
nological status of the patients hospitalized in
those hospitals, as well as the fact that therapy
may be less aggressive in GH (central catheters,
immunosuppressive therapies) than in either TH
or CRC.
It is interesting to compare these data with those
published in the literature. According to two stu-
dies from the US Centers for Disease Control and
Prevention, candidemia accounted for 10% of all
nosocomial bloodstream infections in the USA
during the 1980–89 period, with rates ranging from
five to ten per 10 000 admissions and the incidence
of nosocomial fungal bloodstream infections per
10 000 patients discharged increased from one to
five during the 1980–90 period [3,4]. The Univer-
sity of Iowa Hospitals and Clinics published an
overall rate of nosocomial candidemia of 8.5/
10 000 admissions from 1983 to 1986 [5]. Debusk
et al. reported an incidence of candidemia of 8/
10 000 discharges in 1991 in their hospital in Michi-
gan [6]. Bregenzer et al. reported an incidence of
1.2–6.7/10 000 admissions at Basel University hos-
pital over a 6-year period [7]. In their institution in
Saint Louis (MO, USA), Fraser et al. found an
overall incidence of candidemia of 33/10 000 dis-
charges during a 1-year period (1988–89) and this
represented a 20-fold increase in the incidence of
candidemia in comparison with the period 1976–
79 [8]. In a retrospective survey conducted in five
Dutch University hospitals, Voss et al. found an
incidence of yeast bloodstream infections of 0.34/
10 000 patient-days in 1983, and 0.82/10 000
patient-days in 1993, representing a 240% increase
in 10 years [9]. This incidence was, however, lower
than the incidence rates reported elsewhere. The
same authors reported an incidence of 5.5 per
10 000 patient-days in ICU patients who are known
to be at high risk for nosocomial infections [10]. In
a cancer center in Italy, Girmenia and Martino
reported an overall incidence of 15.5 episodes of
candidemia/10 000 admissions [11].
The overall incidence rate of candidemia was
lower in France in comparison to those published
rates. This finding is important because it suggests
that the results of most published studies coming
from large tertiary-care referral centers in the USA
or elsewhere are biased, since these studies prob-
ably included the most severely ill patients and
may be not representative of the whole population
of hospitalized patients.
Irrespective of the hospital category, this study
showed a marked predominance of C. albicans as
the causative agent of candidemia, accounting for
more than half of the candidemia, distantly fol-
lowed by C. parapsilosis and C. glabrata. Overall,
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47% of the candidemia cases were due to non-
albicans Candida species.
A noticeable change in the Candida species caus-
ing bloodstream infections has been reported by
many authors, also showing that non-albicans
Candida species were responsible for almost 50%
of the candidemia. In the national surveillance
program of nosocomial bloodstream infections
conducted in the USA in 1995–96, C. albicans repre-
sented 52% of strains, C. glabrata 20%, C. tropicalis
11% and C. parapsilosis 8% [1]. In the International
Surveillance of Bloodstream Infections conducted
in the USA, Canada and South America in 1997,
53.3% of candidemia cases were due to C. albicans,
15.7% were due to C. parapsilosis, 15.0% to C.
glabrata and 7.8% to C. tropicalis [12]. However,
the distribution varied by country, and in parti-
cular, in the USA, C. glabrata represented the
second most common non-albicans Candida species
with 18.7% (C. parapsilosis 8.9%), vs. 11.5% in
Canada (C. parapsilosis 22.9%) and only 2.4% in
South America (C. parapsilosis 38.1%). The compar-
ison between 1997 and 1998 in the same countries
showed a slight decrease for C. albicans (from 56.2
to 54.4%) in the USA and an increase in both
Canada (from 52.6 to 70.1%) and Latin America
(from 40.5% to 44.6%) [13]. C. glabrata remained the
second most common species and increased in all
three geographical areas. In a 3.5-year prospective
study conducted between the years 1990 and 1994
in the USA, Nguyen et al. observed that non-
albicans Candida species surpassed C. albicans dur-
ing the second half of the study, rising significantly
from 40% to 53% of all Candida species responsible
for candidemia [14]. Such results have been
reported in 1999 by Columbo et al. in Brazil with
the following distribution: C. albicans (37%), C.
parapsilosis (25%), C. tropicalis (24%) and C. glabrata
(4%) [15]. In a Canadian tertiary-care hospital,
during 1988–89, the most common Candida species
isolated from blood was C. albicans (63%), followed
by C. tropicalis (17%), C. glabrata (13%) and C.
parapsilosis (6.5%). In a Dutch retrospective study
conducted in five university hospitals during the
period from 1987 to 1995, the increase of non-
albicans Candida species was mainly due to C.
glabrata [9]. In candidemic patients with hemato-
logical malignancy, Martino et al. observed an
increasing incidence of C. parapsilopsis, from 8%
to 30% from 1987 to 1990. The incidence continued
to rise during the 1991–94 period when more
than one-third of all candidemic episodes were
ascribed to this species [16]. The emergence of C.
parapsilosis as the predominant Candida species
causing candidemia in children has also been
reported [17].
In our study, candidemias were hospital acquir-
ed in 70–85% of cases and, not surprisingly, most
of these patients were hospitalized in units where
invasive procedures are usual, i.e. ICU and surgi-
cal units, or were immunocompromised patients
hospitalized in hematology or oncology units.
In a survey conducted at the University of Iowa
Hospitals and Clinics, approximately 25% of the
cases of candidemia occurred in surgical ICU, 20%
in the medical ICU, 10% in hematology and oncol-
ogy units and 25% in the bone marrow transplant
unit [18]. Data from the National Nosocomial
Infections Surveillance (NNIS) system indicated
that the highest rates of Candida sp. infections were
found among patients in burn/trauma units (16/
1000 discharges) and among cardiac surgery
patients (11/1000 discharges) [4].
The analysis of the underlying diseases showed
an association between the occurrence of candide-
mia and the presence of malignant diseases, with
cancer patients accounting for half of all the cases
of candidemia, and 23% of the patients were neu-
tropenic. The other most frequent underlying dis-
eases were diabetes and trauma.
The portal of entry of the yeast was unknown in
the majority of patients with candidemia. As might
be expected in these specific populations which
can account for most cases of candidemia, the
leading portal of entry identified was a central
venous catheter, which was present in 60% of
patients and presumed to be at the origin of the
candidemia in 26% of the patients (mainly for
cases of C. parapsilosis which is a saprophyte of
the skin). The second most common portal of entry
was the digestive tract (11%). It is noteworthy that,
as in most other studies, treatment with broad-
spectrum antibiotics was associated with candide-
mia in a majority of patients.
A prospective study in cancer patients reported
in 1999 by the EORTC showed that C. glabrata was
related to the highest mortality in a univariate ana-
lysis [19]. Yamamura et al., in a study carried out
from 1992 to 1994 in Canada, found that despite the
availability of effective antifungal treatment, the
mortality rate related to candidemia was 19% [20].
In conclusion, this survey on the epidemiology
of Candida species in hospitalized patients in
France confirmed the role of Candida species in
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nosocomial bloodstream infections and showed
that, even if C. albicans remains the predominant
species causing candidemia, the role of non-albi-
cans species was important.
If the mortality rate related to candidemia is
19%, the extrapolated French data represented
about 300 deaths in 1995 [20]. The results of this
survey emphasize the need for surveillance of both
Candida spp. infections and antifungal resistance
in France in order to optimize the control and
prevention of yeast infections.
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